Abstract
Purpose
The platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy.
Methods
A retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan–Meier method, and multivariate analysis was performed by using the Cox proportional hazard model.
Results
The cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26–5.45; P = 0.011) and 3.61 (95 % CI, 1.08–12.64; P = 0.038, respectively).
Conclusions
The PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.
Similar content being viewed by others
References
Rodríguez-Moranta F, Saló J, Arcusa A et al (2010) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:386–393
Galizia G, Gemei M, Orditura M et al (2013) Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg 17:1809–1818
Bae SJ, Shin US, Ki YJ, Cho SS, Moon SM, Park SH (2014) Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann Coloproctol 30:266–273
Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944
Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029
Kumar A, Kennecke HF, Renouf DJ, et al (2014) Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer
O'Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381–3388
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Kawai K, Watanabe T (2014) Colorectal cancer and hypercoagulability. Surg Today 44:797–803
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134
**e X, Luo KJ, Hu Y, Wang JY, Chen J (2014) Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus
Lee S, Oh SY, Kim SH et al (2013) Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13:350
Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273
Ying HQ, Deng QW, He BS et al (2014) The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol 31:305
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–4
Benson AB, Bekaii-Saab T, Chan E et al (2013) Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 11:519–528
Zhang JX, Song W, Chen ZH et al (2013) Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 14:1295–1306
Maak M, Simon I, Nitsche U et al (2013) Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 257:1053–1058
Canna K, McArdle PA, McMillan DC et al (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651–654
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318–324
Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H (2010) Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 5:47
Cézé N, Thibault G, Goujon G et al (2011) Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 68:1305–1313
Trousseau A, Phlegmasia alba dolens (1865) Lectures on clinical medicine, delivered at the Holte-Dieu. Paris 5:281–332
Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J (2012) Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 36:192–200
Son HJ, Park JW, Chang HJ et al (2013) Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 20:2908–2913
Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185
Szkandera J, Pichler M, Absenger G et al (2014) The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 208:210–214
Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 31:239
Baranyai Z, Krzystanek M, Jósa V et al (2014) The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost 111:483–490
Disclosure
All of authors declare no conflicts of interest or financial ties to disclosure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozawa, T., Ishihara, S., Nishikawa, T. et al. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer. Int J Colorectal Dis 30, 1165–1171 (2015). https://doi.org/10.1007/s00384-015-2276-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-015-2276-9